NEW YORK (GenomeWeb) – Locus Biosciences said today that is has acquired EpiBiome's high-throughput bacteriophage discovery platform.

Locus is developing CRISPR-Cas3-engineered precision antibacterial products, and aims to pair EpiBiome's phage isolation and characterization system with its own CRISPR-based synthetic biology platform to develop products to treat antibiotic-resistant bacterial infections and precisely edit the microbiome. Terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.